MA37672A1 - Formulation d'agoniste des récepteurs à la somatostatine - Google Patents
Formulation d'agoniste des récepteurs à la somatostatineInfo
- Publication number
- MA37672A1 MA37672A1 MA37672A MA37672A MA37672A1 MA 37672 A1 MA37672 A1 MA 37672A1 MA 37672 A MA37672 A MA 37672A MA 37672 A MA37672 A MA 37672A MA 37672 A1 MA37672 A1 MA 37672A1
- Authority
- MA
- Morocco
- Prior art keywords
- weight
- forming
- somatostatin receptor
- compositions
- receptor agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur des compositions formant un mélange de faible viscosité de : a) 20-50 % en poids d'au moins un diacylglycérol ; b) 20-54 % en poids d'au moins une phosphatidylcholine (pc) ; c) 5-15 % en poids d'au moins un solvant monoalcoolique organique biocompatible ; d) 1 à 20 % en poids d'un solvant polaire ; e) 5 à 150 mg/ml d'au moins un agoniste peptidique des récepteurs à la somatostatine comprenant du pasireotide ; f) éventuellement au moins un antioxydant ; le rapport des composants a:b étant dans la plage de 40:60 à 54:46 ; la préformulation formant, ou pouvant former, au moins une structure de phase à cristaux liquides au contact avec un fluide aqueux en excès. L'invention porte en outre sur des procédés de traitement comprenant l'administration de telles compositions et sur des dispositifs d'administration préremplis et des trousses contenant les formulations.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/059917 WO2012160213A1 (fr) | 2011-05-25 | 2012-05-25 | Formulations peptidiques à libération contrôlée |
| US201261730613P | 2012-11-28 | 2012-11-28 | |
| PCT/EP2013/060739 WO2013174978A1 (fr) | 2012-05-25 | 2013-05-24 | Formulation d'agoniste des récepteurs à la somatostatine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37672A1 true MA37672A1 (fr) | 2016-07-29 |
Family
ID=49623188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37672A MA37672A1 (fr) | 2012-05-25 | 2013-05-24 | Formulation d'agoniste des récepteurs à la somatostatine |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11672843B2 (fr) |
| JP (1) | JP6374380B2 (fr) |
| KR (1) | KR102139080B1 (fr) |
| CN (1) | CN104487050B (fr) |
| AU (1) | AU2013265210B2 (fr) |
| BR (1) | BR112014029425A2 (fr) |
| CA (1) | CA2874367C (fr) |
| CL (1) | CL2014003185A1 (fr) |
| CO (1) | CO7160067A2 (fr) |
| DK (1) | DK2861209T3 (fr) |
| EA (1) | EA035495B1 (fr) |
| ES (1) | ES2834318T3 (fr) |
| HK (1) | HK1207985A1 (fr) |
| IL (1) | IL235740A0 (fr) |
| IN (1) | IN2014DN09831A (fr) |
| MA (1) | MA37672A1 (fr) |
| MX (1) | MX350964B (fr) |
| NZ (1) | NZ702028A (fr) |
| PE (1) | PE20150195A1 (fr) |
| PH (1) | PH12014502614A1 (fr) |
| SG (1) | SG11201407678YA (fr) |
| TN (1) | TN2014000483A1 (fr) |
| WO (1) | WO2013174978A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1768650T3 (pl) * | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| BR112013030104A8 (pt) * | 2011-05-25 | 2021-09-08 | Camurus Ab | Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit |
| MX383392B (es) * | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| CN113018248B (zh) * | 2019-12-23 | 2022-07-22 | 南京清普生物科技有限公司 | 一种缓释递药系统 |
| CN114240934B (zh) * | 2022-02-21 | 2022-05-10 | 深圳大学 | 一种基于肢端肥大症的图像数据分析方法及系统 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5340802A (en) | 1989-06-30 | 1994-08-23 | Abbott Laboratories | Peptide analog type-B CCK receptor ligands |
| CA2535463A1 (fr) | 1989-07-07 | 1991-01-08 | Novartis Ag | Octreotide-pamoate et son utilisation dans des formulations de peptides hydrosolubles a liberation prolongee |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| WO1993006921A1 (fr) | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particules, procede de preparation desdites particules et utilisations |
| US5531925A (en) | 1991-10-04 | 1996-07-02 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
| US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| AU685262B2 (en) | 1994-03-30 | 1998-01-15 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
| SE518578C2 (sv) | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| FR2725369B1 (fr) | 1994-10-07 | 1997-01-03 | Oreal | Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire |
| EP0871489A1 (fr) | 1995-10-12 | 1998-10-21 | Gs Development Ab | Composition pharmaceutique pour l'administration d'un principe actif sur ou au travers d'une surface cutanee ou muqueuse |
| US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| AU6919598A (en) | 1997-04-17 | 1998-11-13 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
| US6638621B2 (en) | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US20040018241A1 (en) | 1997-09-26 | 2004-01-29 | Noven Pharmaceuticals, Inc. | Bioadhesive compositions and methods for topical administration of active agents |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| SI1140148T1 (sl) | 1998-12-22 | 2006-04-30 | Lilly Co Eli | Stabilna formulacija raztopine glukagonu podobnega peptida-1 |
| US6011067A (en) | 1999-06-11 | 2000-01-04 | Thione International, Inc. | Antioxidant composition for the treatment of psoriasis and related diseases |
| GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
| US7008646B2 (en) | 2001-02-20 | 2006-03-07 | Patrick Thomas Spicer | Cubic liquid crystalline compositions and methods for their preparation |
| US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| WO2003000236A1 (fr) | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particules a capacite de solubilisation amelioree |
| ES2298378T3 (es) | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
| JP4733922B2 (ja) | 2002-01-10 | 2011-07-27 | インペリアル・イノベ−ションズ・リミテッド | 摂食行動の修正 |
| US7622118B2 (en) | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| GB0305941D0 (en) | 2003-03-14 | 2003-04-23 | Camurus Ab | Composition |
| GB0307777D0 (en) | 2003-04-04 | 2003-05-07 | Medical Res Council | Conjugate compounds |
| US9522377B2 (en) | 2003-08-04 | 2016-12-20 | Camurus Ab | Method for improving the properties of amphiphile particles |
| WO2005021022A2 (fr) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Formulations de peptides stables |
| GB0322033D0 (en) | 2003-09-19 | 2003-10-22 | Camurus Ab | Composition |
| PL1682091T3 (pl) | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| WO2005063213A1 (fr) | 2003-12-19 | 2005-07-14 | Biodelivery Sciences International, Inc. | Compositions cochleaires liposomales rigides et leurs procedes de fabrication |
| GB0401513D0 (en) | 2004-01-23 | 2004-02-25 | Camurus Ab | Compositions |
| PL1713446T3 (pl) | 2004-01-23 | 2011-05-31 | Camurus Ab | Nielamelarne trójskładnikowe kompozycje lipidów |
| PL1768650T3 (pl) | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| JP5513713B2 (ja) | 2004-08-04 | 2014-06-04 | カムルス エービー | 非層状分散を生じる組成物 |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| PL1845942T3 (pl) | 2005-01-14 | 2014-07-31 | Camurus Ab | Preparaty analogu GnRH |
| PL1848403T3 (pl) | 2005-01-14 | 2010-09-30 | Camurus Ab | Preparaty bioadhezyjne o działaniu miejscowym |
| EP1843746B1 (fr) | 2005-01-14 | 2011-03-16 | Camurus Ab | Formulations à base d'analogues de somatostatine |
| AU2005325510B2 (en) | 2005-01-21 | 2009-07-02 | Camurus Ab | Pharmaceutical lipid compositions |
| US8097239B2 (en) | 2005-06-06 | 2012-01-17 | Camurus Ab | Controlled-release formulations |
| PL1888031T3 (pl) | 2005-06-06 | 2013-04-30 | Camurus Ab | Preparaty analogu glp-1 |
| EP1948271B1 (fr) | 2005-11-17 | 2013-10-02 | Zogenix, Inc. | Administration de preparations visqueuses par injection sans aiguille |
| GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
| PE20090387A1 (es) * | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| US9314508B2 (en) * | 2008-07-08 | 2016-04-19 | Novartis Ag | Use of somatostatin analogs in control of hypoglycemia |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| BR112013030104A8 (pt) * | 2011-05-25 | 2021-09-08 | Camurus Ab | Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit |
| US9555118B2 (en) * | 2011-12-05 | 2017-01-31 | Camrus Ab | Robust controlled-release peptide formulations |
-
2013
- 2013-05-24 PE PE2014002215A patent/PE20150195A1/es not_active Application Discontinuation
- 2013-05-24 US US14/401,559 patent/US11672843B2/en active Active
- 2013-05-24 IN IN9831DEN2014 patent/IN2014DN09831A/en unknown
- 2013-05-24 WO PCT/EP2013/060739 patent/WO2013174978A1/fr not_active Ceased
- 2013-05-24 KR KR1020147036398A patent/KR102139080B1/ko active Active
- 2013-05-24 NZ NZ702028A patent/NZ702028A/en not_active IP Right Cessation
- 2013-05-24 CA CA2874367A patent/CA2874367C/fr active Active
- 2013-05-24 MA MA37672A patent/MA37672A1/fr unknown
- 2013-05-24 EA EA201491928A patent/EA035495B1/ru not_active IP Right Cessation
- 2013-05-24 SG SG11201407678YA patent/SG11201407678YA/en unknown
- 2013-05-24 BR BR112014029425A patent/BR112014029425A2/pt not_active Application Discontinuation
- 2013-05-24 MX MX2014014379A patent/MX350964B/es active IP Right Grant
- 2013-05-24 DK DK13724299.6T patent/DK2861209T3/da active
- 2013-05-24 HK HK15108712.3A patent/HK1207985A1/xx unknown
- 2013-05-24 JP JP2015513209A patent/JP6374380B2/ja active Active
- 2013-05-24 ES ES13724299T patent/ES2834318T3/es active Active
- 2013-05-24 AU AU2013265210A patent/AU2013265210B2/en active Active
- 2013-05-24 CN CN201380034030.8A patent/CN104487050B/zh active Active
-
2014
- 2014-11-17 IL IL235740A patent/IL235740A0/en unknown
- 2014-11-21 TN TN2014000483A patent/TN2014000483A1/fr unknown
- 2014-11-24 CL CL2014003185A patent/CL2014003185A1/es unknown
- 2014-11-24 PH PH12014502614A patent/PH12014502614A1/en unknown
- 2014-12-18 CO CO14278535A patent/CO7160067A2/es unknown
-
2023
- 2023-04-26 US US18/307,124 patent/US20230372436A1/en not_active Abandoned
-
2025
- 2025-01-17 US US19/028,330 patent/US20260000730A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013174978A1 (fr) | 2013-11-28 |
| US11672843B2 (en) | 2023-06-13 |
| AU2013265210A1 (en) | 2014-12-04 |
| US20260000730A1 (en) | 2026-01-01 |
| US20150105332A1 (en) | 2015-04-16 |
| IL235740A0 (en) | 2015-01-29 |
| DK2861209T3 (da) | 2020-12-21 |
| KR20150016977A (ko) | 2015-02-13 |
| EA035495B1 (ru) | 2020-06-25 |
| NZ702028A (en) | 2016-07-29 |
| PE20150195A1 (es) | 2015-02-27 |
| MX350964B (es) | 2017-09-27 |
| CA2874367C (fr) | 2020-08-18 |
| MX2014014379A (es) | 2015-02-05 |
| SG11201407678YA (en) | 2014-12-30 |
| CA2874367A1 (fr) | 2013-11-28 |
| CO7160067A2 (es) | 2015-01-15 |
| CN104487050A (zh) | 2015-04-01 |
| KR102139080B1 (ko) | 2020-07-29 |
| PH12014502614A1 (en) | 2015-01-21 |
| BR112014029425A2 (pt) | 2017-06-27 |
| EA201491928A1 (ru) | 2015-09-30 |
| ES2834318T3 (es) | 2021-06-17 |
| CL2014003185A1 (es) | 2015-04-24 |
| HK1207985A1 (en) | 2016-02-19 |
| IN2014DN09831A (fr) | 2015-08-07 |
| US20230372436A1 (en) | 2023-11-23 |
| JP6374380B2 (ja) | 2018-08-15 |
| JP2015520762A (ja) | 2015-07-23 |
| AU2013265210B2 (en) | 2016-09-15 |
| TN2014000483A1 (en) | 2016-03-30 |
| CN104487050B (zh) | 2019-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015004871A2 (pt) | composição para formação de revestimento sólido e junta tubular rosqueada | |
| BR112014032695A2 (pt) | formulações estáveis para injeção parenteral de fármacos de pequenas moléculas | |
| EA201291108A1 (ru) | Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген | |
| MA38698A1 (fr) | Système d'administration transdermique | |
| CL2013003365A1 (es) | Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros. | |
| SV2005002044A (es) | Solidos supersaturados estabilizados de drogas lipofilicas ref. p-sv-77.892/gh | |
| AR089673A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| EA201491685A1 (ru) | Препарат для инъекций | |
| AR083016A1 (es) | Formulaciones liquidas para la agricultura con una mejor estabilidad | |
| AR033221A1 (es) | Composicion farmaceutica finamente autoemulsionable | |
| BR112012023455A2 (pt) | composição de material, preparação e uso da mesma | |
| CU23814A3 (es) | Emulsión intravenosa de butilftalida y aplicación de la misma | |
| AR081535A1 (es) | Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso | |
| AR045906A1 (es) | Composicion farmaceutica para mejorar la solubilidad de farmacos hidrofobicos | |
| FR2999924B1 (fr) | Association d'actifs comprenant au moins une huile essentielle, une cyclodextrine et un corps gras liquide et composition la contenant. | |
| BRPI0506812A (pt) | composição base auto-microemulsificável, microemulsão e método de preparação da composição base auto-microemulsificável | |
| CO6602159A2 (es) | Formulaciones de aceite que comprenden compuestos de ciclopropeno | |
| RU2014115278A (ru) | Косметическая эмульсия типа "масло в воде" | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| EA201171407A1 (ru) | Способ и композиция для борьбы с эктопаразитами | |
| MX2021003766A (es) | Formulaciones de anticuerpos anti-fgfr2. | |
| TN2014000483A1 (en) | Somatostatin receptor agonist formulations | |
| EP2047857A4 (fr) | Agent destiné à être utilisé pour une injection comprenant un antibiotique et solution pour injection comprenant l'agent | |
| PY2077235A (es) | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x | |
| WO2008077772A3 (fr) | Combinaison d'un composé rétinoïde et d'un agent anticancéreux à base de platine |